Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkins Lymphoma

Trial Profile

Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkins Lymphoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Obinutuzumab (Primary) ; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors PrECOG
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Mar 2017 Status changed from completed to discontinued due to prolonged enrollment timelines
    • 03 Aug 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top